222 related articles for article (PubMed ID: 38066919)
1. Atypical CML: diagnosis and treatment.
Breccia M
Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):476-482. PubMed ID: 38066919
[TBL] [Abstract][Full Text] [Related]
2. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
[TBL] [Abstract][Full Text] [Related]
3. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management.
Szuber N; Orazi A; Tefferi A
Am J Hematol; 2024 Apr; ():. PubMed ID: 38644693
[TBL] [Abstract][Full Text] [Related]
4. Atypical Chronic Myeloid Leukemia: Where Are We Now?
Crisà E; Nicolosi M; Ferri V; Favini C; Gaidano G; Patriarca A
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962122
[TBL] [Abstract][Full Text] [Related]
5. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
[TBL] [Abstract][Full Text] [Related]
6. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
[TBL] [Abstract][Full Text] [Related]
7. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
Tiu RV; Sekeres MA
Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
[TBL] [Abstract][Full Text] [Related]
8. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Patnaik MM; Lasho TL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
[TBL] [Abstract][Full Text] [Related]
9. Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia.
Patnaik MM; Barraco D; Lasho TL; Finke CM; Reichard K; Hoversten KP; Ketterling RP; Gangat N; Tefferi A
Am J Hematol; 2017 Jun; 92(6):542-548. PubMed ID: 28314085
[TBL] [Abstract][Full Text] [Related]
10. ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia.
Shuai W; Zuo Z; Li N; Garces S; Jelloul FZ; Ok CY; Li S; Xu J; You MJ; Wang W; Rehder C; Jabbour EJ; Patel KP; Medeiros LJ; Yin CC
Cancer; 2023 Mar; 129(6):878-889. PubMed ID: 36583229
[TBL] [Abstract][Full Text] [Related]
11. Current and evolving understanding of atypical chronic myeloid leukemia.
Schwartz LC; Mascarenhas J
Blood Rev; 2019 Jan; 33():74-81. PubMed ID: 30078497
[TBL] [Abstract][Full Text] [Related]
12. [Molecular characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia].
Senín A; Arenillas L; Martínez-Avilés L; Fernández-Rodríguez C; Bellosillo B; Florensa L; Besses C; Álvarez-Larrán A
Med Clin (Barc); 2015 Jun; 144(11):487-90. PubMed ID: 24854193
[TBL] [Abstract][Full Text] [Related]
13. Myelodysplastic/myeloproliferative neoplasm with neutrophilia (atypical chronic myeloid leukemia-aCML).
Martino G; Quintini M; Martelli MP; Ascani S; Lazzi S; Mecucci C
Am J Hematol; 2023 Jul; 98(7):1163-1164. PubMed ID: 36594191
[TBL] [Abstract][Full Text] [Related]
14. Characteristics, primary treatment, and survival of MDS/MPN with neutrophilia: a population-based study.
Klein SK; Huls GA; Visser O; Kluin-Nelemans HC; Dinmohamed AG
Blood Adv; 2023 Dec; 7(24):7554-7563. PubMed ID: 37934881
[TBL] [Abstract][Full Text] [Related]
15. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T.
Talati C; Padron E
Curr Hematol Malig Rep; 2016 Dec; 11(6):425-433. PubMed ID: 27664113
[TBL] [Abstract][Full Text] [Related]
16. Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions.
Muramatsu H; Makishima H; Maciejewski JP
Semin Oncol; 2012 Feb; 39(1):67-73. PubMed ID: 22289493
[TBL] [Abstract][Full Text] [Related]
17. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.
Palomo L; Meggendorfer M; Hutter S; Twardziok S; Ademà V; Fuhrmann I; Fuster-Tormo F; Xicoy B; Zamora L; Acha P; Kerr CM; Kern W; Maciejewski JP; Solé F; Haferlach C; Haferlach T
Blood; 2020 Oct; 136(16):1851-1862. PubMed ID: 32573691
[TBL] [Abstract][Full Text] [Related]
18.
Iaquinta G; Scalzulli E; Angeloni S; Carmosino I; Costa A; Ielo C; Passucci M; Masucci C; Martelli M; Grammatico P; Breccia M
Leuk Lymphoma; 2023 Oct; 64(10):1730-1732. PubMed ID: 37435984
[TBL] [Abstract][Full Text] [Related]
19. Trametinib: Could It Be a Promising Drug to Treat Atypical Chronic Myeloid Leukemia?
Elsayed M; Harry S; Nanua S; Zaidi S; Habib MH; Raza S
Cureus; 2022 Jul; 14(7):e26619. PubMed ID: 35949766
[TBL] [Abstract][Full Text] [Related]
20. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes.
Carreño-Tarragona G; Álvarez-Larrán A; Harrison C; Martínez-Ávila JC; Hernández-Boluda JC; Ferrer-Marín F; Radia DH; Mora E; Francis S; González-Martínez T; Goddard K; Pérez-Encinas M; Narayanan S; Raya JM; Singh V; Gutiérrez X; Toth P; Amat-Martínez P; Mcilwaine L; Alobaidi M; Mayani K; McGregor A; Stuckey R; Psaila B; Segura A; Alvares C; Davidson K; Osorio S; Cutting R; Sweeney CP; Rufián L; Moreno L; Cuenca I; Smith J; Morales ML; Gil-Manso R; Koutsavlis I; Wang L; Mead AJ; Rozman M; Martínez-López J; Ayala R; Cross NCP
Blood Adv; 2023 May; 7(9):1672-1681. PubMed ID: 36375042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
